Calidi Biotherapeutics -CW23CLDWWPreferred / convertible
13F holders, Q2 2024 (June 30)15holders −1
1new positions
2sold out
1famous investor
$0.04avg. 13F price*
At the end of Q2 2024, 15 institutions reported holding Calidi Biotherapeutics -CW23 (CLDWW) in their 13F filings, down 1 from Q1 2024. 1 opened new positions and 2 sold out. The largest holders were Polar Asset Management Partners Inc. ($76K), Finepoint Capital LP ($28K) and 683 Capital Management, LLC ($25K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Calidi Biotherapeutics -CW23
- CUSIP
- 320703119
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 2 | $6K |
All 13F filers, Q1 2024 → Q2 2024: 74,409 shares bought and 108,912 shares sold, net −34,503 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Polar Asset Management Partners Inc. | — | No change | 2,165,086 | $76K |
| Finepoint Capital LP | — | No change | 655,200 | $28K |
| 683 Capital Management, LLC | — | Reduce -0.1% | 599,702 | $25K |
| Nomura Holdings Inc. | — | No change | 467,818 | $20K |
| Shaolin Capital Management LLC | — | No change | 450,000 | $19K |
| Aristeia Capital, L.L.C. | — | No change | 494,400 | $17K |
| Arena Investors LP | — | No change | 333,333 | $12K |
| Cowen and Company, LLC | — | Reduce -0.3% | 171,536 | $7K |
| Exos Asset Management LLC | — | No change | 105,000 | $4K |
| Citadel Advisors | — | Add +344.2% | 70,501 | $3K |
| Walleye Capital LLC | — | No change | 36,469 | $2K |
| Walleye Trading LLC | — | No change | 20,052 | $844 |
| UBS Group AG | — | Add +2833.1% | 3,901 | $109 |
| Clear Street LLC | — | No change | 1,746 | $74 |
| Flow Traders U.S. LLC | — | New | 16,013 | $0 |
"% of holder's portfolio" is CLDWW's weight in each manager's 13F, not the share of Calidi Biotherapeutics -CW23 the manager owns.